Breaking News, Collaborations & Alliances

Astellas, KateTx Enter Exclusive License Agreement to Develop KT430

Next-gen investigational gene therapy to treat X-linked myotubular myopathy (XLMTM), a life-threatening, rare neuromuscular disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Astellas Pharma Inc. and Kate Therapeutics entered an exclusive license agreement to develop and commercialize KT430. KT430 is a preclinical next-generation investigational gene therapy that delivers a functional copy of the MTM1 gene via a novel MyoAAV capsid to treat X-linked myotubular myopathy (XLMTM), a life-threatening, rare neuromuscular disease characterized by extreme muscle weakness, respiratory failure and early death.   Astellas will make an undisclosed upfront payment to KateTx, w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters